SLC5A2 and metabolic dysfunction-associated steatohepatitis: In the present study, we examined the effects of ipragliflozin, a SGLT2‐selective inhibitor, alone and in combination with pioglitazone on NASH in high‐fat diet‐fed KK/Ay type 2 diabetic mice.